Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mexico clears Biocon's 'biocomparable' insulin glargine

This article was originally published in Scrip

Executive Summary

Mexico has approved Biocon's insulin glargine, the first such product cleared under the Latin American nation's biocomparable approvals pathway defined in 2012. Biocon said that its insulin glargine (Galactus) has been approved by Mexico's Cofepris, through the Indian firm's partner PiSA Farmaceutica. While details on Galactus' pricing were not immediately available, the partners hope to facilitate a lowering of per capita expenditure on diabetes with the use of their "cost effective" insulin glargine. Mexico is estimated to have more than nine million cases of diabetes, with per capita expenditure on the disease as high as $892.5. The market for insulin glargine in Mexico is said to be in excess of $40m, with the overall insulins market estimated at around $150m. The total annual cost of managing diabetes and its complications in Mexico in 2000 was estimated at more than $15bn, of which around $765m represented direct medication costs, data published in the 2003 bulletin of the WHO said.

You may also be interested in...



India Keeps Door Ajar For Hydroxychloroquine Exports, Drug Makers Geared Up

Indian drug makers appear confident of meeting both domestic and global requirements for hydroxychloroquine sulphate after India relaxed export curbs on the product, subject to strict monitoring, against the backdrop of requests from global heads of government for supplies of the potential treatment for COVID-19.

Amid Aborted Sandoz Deal, A Silver Lining For Aurobindo?

The termination of the Aurobindo-Sandoz deal isn’t perhaps all bad news for the Indian firm and the flip side may be an improved balance sheet, according to some analysts. But the resolution of compliance issues at manufacturing facilities remains critical.

Aurobindo-Sandoz End $1bn US Deal

Aurobindo and Sandoz mutually terminate their planned $1bn deal, leaving many questions on how both sides will re-orient strategies going forward.

Topics

Related Companies

UsernamePublicRestriction

Register

SC028390

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel